DB05540InvestigationalSmall molecule
An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
- Mechanism
- Curator reviewed
L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency.
- Primary indication
- Investigated for use/treatment in brain cancer and cancer/tumors (unspecified).Curator reviewed
- Formula / weight
- C3H7N3O4 · 149.1054 g/mol (avg)
- Also known as
- L-Alanosine
- Code names
- SDX-102
Resolves to
Structure
InChIKey
MLFKVJCWGUZWNV-REOHCLBHSA-NSMILESN[C@@H](CN(O)N=O)C(O)=OTransporters
What you can answer from here — as of February 21, 2021
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Alanosine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account